Humanigen (HGEN) Announces Partnership to Commercialize Nasal Spray that Fights COVID Cytokine Storm, Expects EUA - Roth Capital
Tweet Send to a Friend
Roth Capital analyst Tony Butler reiterated a Buy rating and $25.00 price target on Humanigen (NASDAQ: HGEN) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
